208 related articles for article (PubMed ID: 22905972)
1. CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.
Choi JW; Kim Y; Lee JH; Kim YS
Int J Urol; 2013 Feb; 20(2):251-5. PubMed ID: 22905972
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
3. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
4. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
[TBL] [Abstract][Full Text] [Related]
5. [Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma].
Guo YS; Dai YP; Li W; Liu LD
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):28-31. PubMed ID: 21575460
[TBL] [Abstract][Full Text] [Related]
6. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
7. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification.
Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI
J Urol; 2005 Nov; 174(5):1976-80. PubMed ID: 16217372
[TBL] [Abstract][Full Text] [Related]
8. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer.
Marín-Aguilera M; Mengual L; Ribal MJ; Ars E; Ríos J; Gázquez C; Villavicencio H; Alcaraz A
Urology; 2012 Jan; 79(1):240.e9-15. PubMed ID: 22055693
[TBL] [Abstract][Full Text] [Related]
9. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A
Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799
[TBL] [Abstract][Full Text] [Related]
10. Editorial Comment to CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.
Gakis G
Int J Urol; 2013 Feb; 20(2):256-7. PubMed ID: 22934668
[No Abstract] [Full Text] [Related]
11. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
15. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.
Sonpavde G; Khan MM; Lerner SP; Svatek RS; Novara G; Karakiewicz PI; Skinner E; Tilki D; Kassouf W; Fradet Y; Dinney CP; Fritsche HM; Izawa JI; Bastian PJ; Ficarra V; Schoenberg M; Sagalowsky AI; Lotan Y; Shariat SF
J Urol; 2011 Feb; 185(2):456-61. PubMed ID: 21167527
[TBL] [Abstract][Full Text] [Related]
16. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
17. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
[TBL] [Abstract][Full Text] [Related]
18. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
19. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
20. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ
Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
